Conflict of interest: none declared.
Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study
Article first published online: 30 SEP 2005
Clinical and Experimental Dermatology
Volume 30, Issue 6, pages 632–635, November 2005
How to Cite
Wozniacka, A., Wieczorkowska, M., Gebicki, J. and Sysa-Jedrzejowska, A. (2005), Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clinical and Experimental Dermatology, 30: 632–635. doi: 10.1111/j.1365-2230.2005.01908.x
- Issue published online: 30 SEP 2005
- Article first published online: 30 SEP 2005
- Accepted for publication 4 May 2005
Rosacea is a chronic facial dermatosis with a progressive course, which is characterized by the presence of erythema, papules, pustules, telangiectasias and sebaceous gland hyperplasia. However, the aetiology is still unknown; genetic predisposition, gastrointestinal disorders (Helicobacter pylori), infestations with Demodex folliculorum and environmental stimuli are considered to be involved in the inflammatory process. A metabolite of nicotinamide, 1-methylnicotinamide (MNA+), has anti-inflammatory properties, and this is the first study to test the effectiveness of this agent in treating rosacea. In total, 34 patients with rosacea were treated with a gel containing 0.25% MNA+ as a chloride salt, twice daily for 4 weeks, after which improvement was observed in 26/34 cases. The improvement was good in 9/34 and moderate in 17/34, but no clinical effect was noted in seven subjects. In only one case was skin irritation given as the reason for treatment withdrawal. These results indicate that MNA+ might be a useful agent for treating rosacea.